Allakos Competitors

Allakos (NASDAQ:ALLK) and Horizon Therapeutics Public (NASDAQ:HZNP) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

Earnings and Valuation

This table compares Allakos and Horizon Therapeutics Public's gross revenue, earnings per share and valuation.

Horizon Therapeutics Public has higher revenue and earnings than Allakos. Allakos is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

65.4% of Allakos shares are owned by institutional investors. Comparatively, 88.6% of Horizon Therapeutics Public shares are owned by institutional investors. 44.8% of Allakos shares are owned by insiders. Comparatively, 4.3% of Horizon Therapeutics Public shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Allakos has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500. Comparatively, Horizon Therapeutics Public has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500.

Profitability

This table compares Allakos and Horizon Therapeutics Public's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and price targets for Allakos and Horizon Therapeutics Public, as reported by MarketBeat.com.

Allakos presently has a consensus price target of $181.50, suggesting a potential upside of 80.53%. Horizon Therapeutics Public has a consensus price target of $111.3636, suggesting a potential upside of 18.74%. Given Allakos' higher possible upside, analysts clearly believe Allakos is more favorable than Horizon Therapeutics Public.

Summary

Horizon Therapeutics Public beats Allakos on 10 of the 12 factors compared between the two stocks.

Catalent (NYSE:CTLT) and Allakos (NASDAQ:ALLK) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Profitability

This table compares Catalent and Allakos' net margins, return on equity and return on assets.

Institutional & Insider Ownership

97.8% of Catalent shares are held by institutional investors. Comparatively, 65.4% of Allakos shares are held by institutional investors. 1.0% of Catalent shares are held by company insiders. Comparatively, 44.8% of Allakos shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Catalent and Allakos' gross revenue, earnings per share (EPS) and valuation.

Catalent has higher revenue and earnings than Allakos. Allakos is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Catalent has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, Allakos has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Catalent and Allakos, as reported by MarketBeat.

Catalent currently has a consensus target price of $125.1250, suggesting a potential upside of 22.65%. Allakos has a consensus target price of $181.50, suggesting a potential upside of 80.53%. Given Allakos' stronger consensus rating and higher possible upside, analysts plainly believe Allakos is more favorable than Catalent.

Summary

Catalent beats Allakos on 10 of the 13 factors compared between the two stocks.

Elanco Animal Health (NYSE:ELAN) and Allakos (NASDAQ:ALLK) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Profitability

This table compares Elanco Animal Health and Allakos' net margins, return on equity and return on assets.

Institutional & Insider Ownership

86.8% of Elanco Animal Health shares are held by institutional investors. Comparatively, 65.4% of Allakos shares are held by institutional investors. 0.1% of Elanco Animal Health shares are held by company insiders. Comparatively, 44.8% of Allakos shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Elanco Animal Health and Allakos' gross revenue, earnings per share (EPS) and valuation.

Elanco Animal Health has higher revenue and earnings than Allakos. Allakos is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Elanco Animal Health has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Allakos has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Elanco Animal Health and Allakos, as reported by MarketBeat.

Elanco Animal Health currently has a consensus target price of $33.1364, suggesting a potential downside of 5.35%. Allakos has a consensus target price of $181.50, suggesting a potential upside of 80.53%. Given Allakos' stronger consensus rating and higher possible upside, analysts plainly believe Allakos is more favorable than Elanco Animal Health.

Summary

Elanco Animal Health beats Allakos on 7 of the 13 factors compared between the two stocks.

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Allakos (NASDAQ:ALLK) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Profitability

This table compares Alnylam Pharmaceuticals and Allakos' net margins, return on equity and return on assets.

Institutional & Insider Ownership

92.4% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 65.4% of Allakos shares are held by institutional investors. 3.5% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 44.8% of Allakos shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Alnylam Pharmaceuticals and Allakos' gross revenue, earnings per share (EPS) and valuation.

Allakos has lower revenue, but higher earnings than Alnylam Pharmaceuticals. Allakos is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Alnylam Pharmaceuticals has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, Allakos has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Alnylam Pharmaceuticals and Allakos, as reported by MarketBeat.

Alnylam Pharmaceuticals currently has a consensus target price of $168.7333, suggesting a potential upside of 24.17%. Allakos has a consensus target price of $181.50, suggesting a potential upside of 80.53%. Given Allakos' stronger consensus rating and higher possible upside, analysts plainly believe Allakos is more favorable than Alnylam Pharmaceuticals.

Summary

Allakos beats Alnylam Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Zai Lab (NASDAQ:ZLAB) and Allakos (NASDAQ:ALLK) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Zai Lab and Allakos, as reported by MarketBeat.

Zai Lab currently has a consensus target price of $197.8460, suggesting a potential upside of 28.48%. Allakos has a consensus target price of $181.50, suggesting a potential upside of 80.53%. Given Allakos' higher possible upside, analysts plainly believe Allakos is more favorable than Zai Lab.

Profitability

This table compares Zai Lab and Allakos' net margins, return on equity and return on assets.

Volatility and Risk

Zai Lab has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, Allakos has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.

Valuation & Earnings

This table compares Zai Lab and Allakos' gross revenue, earnings per share (EPS) and valuation.

Allakos has lower revenue, but higher earnings than Zai Lab. Allakos is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

81.3% of Zai Lab shares are held by institutional investors. Comparatively, 65.4% of Allakos shares are held by institutional investors. 44.8% of Allakos shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Allakos beats Zai Lab on 6 of the 11 factors compared between the two stocks.

Allakos (NASDAQ:ALLK) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.

Analyst Ratings

This is a summary of recent recommendations for Allakos and BioMarin Pharmaceutical, as provided by MarketBeat.com.

Allakos currently has a consensus target price of $181.50, suggesting a potential upside of 80.53%. BioMarin Pharmaceutical has a consensus target price of $118.20, suggesting a potential upside of 52.83%. Given Allakos' stronger consensus rating and higher possible upside, research analysts plainly believe Allakos is more favorable than BioMarin Pharmaceutical.

Profitability

This table compares Allakos and BioMarin Pharmaceutical's net margins, return on equity and return on assets.

Risk & Volatility

Allakos has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500.

Earnings and Valuation

This table compares Allakos and BioMarin Pharmaceutical's revenue, earnings per share (EPS) and valuation.

BioMarin Pharmaceutical has higher revenue and earnings than Allakos. Allakos is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

65.4% of Allakos shares are held by institutional investors. Comparatively, 97.7% of BioMarin Pharmaceutical shares are held by institutional investors. 44.8% of Allakos shares are held by insiders. Comparatively, 2.2% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

BioMarin Pharmaceutical beats Allakos on 9 of the 13 factors compared between the two stocks.